The reality of neonatal respiratory distress and what actually helps
Surfactant therapy in neonates is one of those things that sounds simple on paper but gives you real headaches at 3 AM when the dose isn't taking. I spent roughly four years in a NICU rotating through respiratory management, and surfactant administration still catches people off guard. The mechanism itself is straightforward. Surfactants reduce surface tension in the alveoli, preventing collapse at end-expiration. Premature infants simply do not produce enough of their own. The medication you administer externally bridges that gap until the type II pneumocytes start doing their job, which typically happens around 34 to 36 weeks gestation. The main formulations you will encounter are poractant alfa (Curosurf), beractant (Surfactant-TA), calfactant (Survanta), and lucinactant (Surfaxin). Poractant alfa comes from bovine lung extract and is dosed at 100 to 200 mg/kg per dose. Beractant is also bovine-derived, dosed similarly at 100 to 200 mg/kg. Calfactant is bovine and palmitoyl-oleoyl phosphatidylcholine based. Lucinactant is synthetic, which matters because it has a different lipid profile and slightly different handling requirements. Natural extract surfactants generally outperform synthetic ones in outcomes, but the synthetic option exists for specific cases or supply constraints. The standard indication is infant respiratory distress syndrome, that's RDS, in preterm neonates under 30 weeks gestation or with confirmed surfactant deficiency. You administer it via intratracheal instillation through an umbilical or endotracheal catheter. The classic dose is 1 to 4 doses spaced 6 to 12 hours apart, though some protocols use a single dose only. The total cumulative dose rarely exceeds 400 mg/kg.
Here is the part most sources skip. The administration technique actually matters more than the drug choice in many cases. I saw a case once where a seemingly adequate dose of beractant produced zero clinical improvement. The problem was not the surfactant. The baby had significant meconium contamination in the airway, and the meconium inactivated the surfactant before it could spread across the alveolar surface. We cleared the airway first with direct laryngoscopy and suction, then re-administered. The second dose worked immediately. Oxygenation improved within minutes. Arousal scores went up. That case changed how I approach every surfactant administration after that. The positioning during and after instillation is non-negotiable. You instill the surfactant in four positions: supine, right lateral, supine again, left lateral. Each position gets roughly a quarter of the total dose. You let each aliquot sit for about 30 seconds before turning the infant. This mechanical redistribution is what actually gets the surfactant to the dependent lung regions. If you just dump the whole volume in and leave the baby flat, you are relying on diffusion alone, and that process is too slow in a sick lung with poor compliance. Premedication matters too. You should have the infant intubated and connected to the ventilator before administration. Suction before the dose. Have oxygen ready at 100 percent because desaturation during the procedure is almost guaranteed. The surfactant temporarily worsens gas exchange as it spreads and disrupts the existing fluid interface. I usually pre-oxygenate for 30 seconds, give the dose over two to three minutes, and then resume ventilation. Permissive hypercapnia during the procedure is acceptable. Blood gases will swing, and that is normal.
Side effects are real and you need to watch for them. Intraventricular hemorrhage risk increases slightly, particularly in extremely low birth weight infants below 1000 grams. Pulmonary hemorrhage is rare but catastrophic when it happens. Bradycardia and desaturation during administration are common and usually self-limiting. Air leaks, pneumothorax and pneumomediastinum, remain a concern because the underlying lung disease is fragile regardless of the surfactant. The benefit overwhelmingly outweighs these risks in appropriate candidates, but you are not removing the risk entirely by giving the drug. One thing people get wrong is the timing of the second dose. There is a tendency to wait the full 12 hours between doses if the first one seems partially effective. In practice, if oxygen requirement is not improving meaningfully after 90 minutes, a second dose is usually indicated regardless of the clock. The lung compliance curve does not wait for your protocol sheet. I have seen infants deteriorate because someone adhered to a rigid scheduling window instead of responding to the physiology in front of them. Storage and preparation are another area where mistakes creep in. Curosurf comes as a suspension that must be warmed to room temperature before use. Do not shake it. Invert gently if needed. Beractant also requires warming but is more forgiving on handling. Lucinactant is reconstituted differently and has a shorter usable window once mixed. If you send a dose back to the fridge after it has been drawn up, it is contaminated. Single-use vials exist for this reason. Never split a vial across patients.
Get the Full Details
The pharmacokinetics are interesting and somewhat counterintuitive. Surfactant does not circulate systemically in any meaningful amount. It stays in the airspaces and is gradually cleared by alveolar macrophages and epithelial lining fluid turnover. That is why dosing is based on intratracheal delivery, not intravenous. Serum levels are undetectable. The half-life within the lung is measured in hours, which is why repeated doses are sometimes needed as the infant's own production ramps up. I mentioned earlier that synthetic surfactants underperform natural extract surfactants. The data supports this. POROSURF and other meta-analyses show lower mortality and fewer air leaks with natural surfactants. The synthetic option with CL-2000, the lucinactant molecule, was supposed to close that gap. It did not fully do so. It is still useful when natural surfactant is contraindicated or unavailable, but do not pretend they are equivalent. There is a newer delivery method worth noting. INSURE, which stands for INtubate-SURfactant-EXTubate. You intubate, give surfactant, then extubate to continuous positive airway pressure within an hour. This avoids prolonged mechanical ventilation and its associated complications. It works well for infants who are breathing adequately after surfactant administration but need support. The alternative, PROPHYLAXIS, is giving surfactant within the first hour of life before any intubation attempt, followed by early CPAP. LATE SURFACTANT is the traditional approach for infants already on the ventilator with established RDS. All three strategies have their place. Choice depends on gestational age, severity, and local protocol.
The biggest mistake I see in practice is under-dosing. People feel guilty giving the full recommended dose, especially to tiny babies, and they trim it. This is unnecessary. The dosing is weight-based and well studied. Under-dosing simply means incomplete coverage and the need for repeat administration, which increases procedural risk without gaining anything. If the protocol says 200 mg/kg, give 200 mg/kg. The evidence base supports this. Another oversight is failing to adjust ventilator settings appropriately after administration. You should expect improved compliance. If you do not adjust peak inspiratory pressure and mean airway pressure downward accordingly, you risk volutrauma on a lung that is suddenly much easier to inflate. The same lung that needed 25 cm H2O before may respond at 18 after surfactant. Monitoring trends, not single values, guides these adjustments. Adult acute respiratory distress syndrome has been attempted with surfactant therapy with mixed results. The adult lung pathology is different. The damage is more diffuse and inflammatory, not primarily a surfactant deficiency. Some studies show transient improvement in oxygenation but no mortality benefit. This is not a straightforward translation from neonates to adults. Do not extrapolate neonatal success to adult practice without strong evidence.
The cost is another practical consideration. A single dose of poractant alfa runs roughly $800 to $1200 depending on hospital formulary and volume discounts. Multiple doses stack up fast. Insurance coverage varies. Prior authorization delays can be frustrating but are rarely a barrier in emergency situations for covered patients. Generic biosimilar surfactants are emerging in some markets and may change the economics in the next few years. If you are working in a setting without neonatal intensive care capabilities, transfer decisions around surfactant timing are critical. Do not wait for the baby to stabilize before transferring. Do not give surfactant and then delay transfer for days. The window where surfactant makes the most difference is early, before extensive lung injury develops. Coordinate with the receiving center before administration if possible, but do not hold the drug for transport logistics. Long-term outcomes with surfactant therapy are generally positive. Reduced mortality from respiratory failure. Decreased chronic lung disease severity in survivors. Better neurodevelopmental outcomes compared to historical controls before surfactant was available. The drug itself is not associated with long-term toxicity because it is not systemically absorbed. The risks are procedural and acute, not cumulative.
The bottom line is that surfactant is a time-sensitive intervention with a narrow window of optimal effectiveness. Technique matters as much as the molecule. Positioning, dosing accuracy, ventilator adjustments, and recognition of when to repeat are all skills that improve with experience. The drug will not save a lung that is mistreated around it. Pay attention to the process, not just the prescription.
